Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The earnings per share (EPS) is N/A as of the fiscal period ended Monday, June 30, 2025.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2025-12-31): -0.01.
EARNINGS PER SHARE (EPS)
N/A
EARNINGS PER SHARE (EPS) AVG TTM
-0.01
EARNINGS PER SHARE (EPS) AVG 3Y
-0.01
EARNINGS PER SHARE (EPS) AVG 5Y
-0.01
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Regencell Bioscience Holdings Limited
Market Cap
$3.64B
Earnings Per Share (EPS)
N/A
TTM Avg
-0.01
3Y Avg
-0.01
5Y Avg
-0.01
Market Cap
$3.57B
Earnings Per Share (EPS)
-0.85
TTM Avg
-1.03
3Y Avg
-1.09
5Y Avg
-1.06
Market Cap
$3.56B
Earnings Per Share (EPS)
1.40
TTM Avg
0.58
3Y Avg
-0.09
5Y Avg
-0.36
Market Cap
$3.54B
Earnings Per Share (EPS)
-4.74
TTM Avg
-3.69
3Y Avg
-3.04
5Y Avg
-2.46
Market Cap
$3.52B
Earnings Per Share (EPS)
-0.43
TTM Avg
-2.51
3Y Avg
-3.24
5Y Avg
-3.00
Market Cap
$3.48B
Earnings Per Share (EPS)
-1.94
TTM Avg
-2.32
3Y Avg
-2.00
5Y Avg
-1.79
Market Cap
$3.47B
Earnings Per Share (EPS)
-4.29
TTM Avg
-3.30
3Y Avg
-2.99
5Y Avg
-2.52
Market Cap
$3.44B
Earnings Per Share (EPS)
-1.17
TTM Avg
-1.00
3Y Avg
-1.15
5Y Avg
-1.50
Market Cap
$3.38B
Earnings Per Share (EPS)
2.22
TTM Avg
1.84
3Y Avg
0.49
5Y Avg
-0.14
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regencell Bioscience Holdings Limited (RGC) | $3.64B | N/A | -0.01 | -0.01 | -0.01 |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | -0.85 | -1.03 | -1.09 | -1.06 |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 1.40 | 0.58 | -0.09 | -0.36 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | -4.74 | -3.69 | -3.04 | -2.46 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | -0.43 | -2.51 | -3.24 | -3.00 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | -1.94 | -2.32 | -2.00 | -1.79 |
| Celcuity Inc. (CELC)vs › | $3.47B | -4.29 | -3.30 | -2.99 | -2.52 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -1.17 | -1.00 | -1.15 | -1.50 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 2.22 | 1.84 | 0.49 | -0.14 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A | -87.94 | -87.94 | -87.94 |
Trailing EPS (TTM)
N/A
Forward EPS (Est.)
N/A
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-06-30 | -0.01 |
| 2024-06-30 | -0.01 |
| 2023-06-30 | -0.01 |
| 2022-06-30 | -0.01 |
| 2021-06-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2019-06-30 | 0.00 |
